Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug …
SM Nikkho, MJ Richter, E Shen, SH Abman… - Pulmonary …, 2022 - Wiley Online Library
Pulmonary hypertension (PH) has been linked to worse outcomes in chronic lung diseases.
The presence of PH in the setting of underlying Interstitial Lung Disease (ILD) is strongly …
The presence of PH in the setting of underlying Interstitial Lung Disease (ILD) is strongly …
Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary …
Pulmonary hypertension (PH) is a frequent complication of interstitial lung disease (ILD).
Although PH has mostly been described in idiopathic pulmonary fibrosis, it can manifest in …
Although PH has mostly been described in idiopathic pulmonary fibrosis, it can manifest in …
Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: a Bayesian retrospective observational cohort study
TJW Dawes, C McCabe, K Dimopoulos, I Stewart… - …, 2023 - Wiley Online Library
Abstract Background and Objective Pulmonary hypertension is a life‐limiting complication of
interstitial lung disease (ILD‐PH). We investigated whether treatment with …
interstitial lung disease (ILD‐PH). We investigated whether treatment with …
Cone beam CT guidance improves transbronchial lung cryobiopsy safety
BS Benn, AO Romero, H Bawaadam, N Ivanick, M Lum… - Lung, 2021 - Springer
Introduction Determining the cause of diffuse parenchymal lung disease (DPLD) is
challenging. While surgical lung biopsy has been the standard approach, transbronchial …
challenging. While surgical lung biopsy has been the standard approach, transbronchial …
Predicting new-onset exertional and resting hypoxemia in fibrotic interstitial lung disease
F Saleem, CJ Ryerson, N Sarma… - Annals of the …, 2023 - atsjournals.org
Rationale: Hypoxemia in fibrotic interstitial lung disease (ILD) indicates disease progression
and is of prognostic significance. The onset of hypoxemia signifies disease progression and …
and is of prognostic significance. The onset of hypoxemia signifies disease progression and …
The impact of nintedanib and pirfenidone on lung function and survival in patients with idiopathic pulmonary fibrosis in real-life setting
G Santos, A Fabiano, PC Mota, I Rodrigues… - Pulmonary …, 2023 - Elsevier
Background Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia
of unknown cause that is associated with radiological and/or histological features of usual …
of unknown cause that is associated with radiological and/or histological features of usual …
[HTML][HTML] Acute exacerbation in interstitial lung disease
EH Alhamad, JG Cal, NN Alrajhi… - Annals of Thoracic …, 2021 - journals.lww.com
BACKGROUND: Information regarding acute exacerbation (AE) in patients with interstitial
lung disease (ILD) is limited. OBJECTIVES: The objective of the study was to elucidate the …
lung disease (ILD) is limited. OBJECTIVES: The objective of the study was to elucidate the …
[HTML][HTML] Dominating cause of pulmonary hypertension may change over time—diagnostic and therapeutic considerations in a patient with pulmonary hypertension …
M Szturmowicz, M Franczuk, ME Jędrych… - Diagnostics, 2021 - mdpi.com
Chronic lung diseases are one of the most frequent causes of pulmonary hypertension (PH).
The diagnostic challenge is to differentiate PH due to chronic lung disease from pulmonary …
The diagnostic challenge is to differentiate PH due to chronic lung disease from pulmonary …
[HTML][HTML] Pulmonary hypertension associated mortality in the United States from 2003 to 2020: an observational analysis of time trends and disparities
Background Pulmonary hypertension (PH) is an independent risk factor for morbidity and
mortality. In the last two decades, significant advances have been made in management of …
mortality. In the last two decades, significant advances have been made in management of …
[HTML][HTML] Pulmonary Hypertension in the Course of Interstitial Lung Diseases—A Personalised Approach Is Needed to Identify a Dominant Cause and Provide an …
A Kacprzak, W Tomkowski, M Szturmowicz - Diagnostics, 2023 - mdpi.com
The prevalence of pulmonary hypertension (PH) complicating interstitial lung diseases
(ILDs) is 3.5–15% at an early stage, and up to 90% in ILD patients listed for lung …
(ILDs) is 3.5–15% at an early stage, and up to 90% in ILD patients listed for lung …